Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Next Previous
X
Search
Drug Profile

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Alternative Names: Cyclobenzaprine HCL; cyclobenzaprine HCl sublingual tablets; Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp; Tonix Pharmaceuticals Inc
  • Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Fibromyalgia
  • Phase III Post-traumatic stress disorders
  • Phase II Agitation; Post acute COVID 19 syndrome
  • No development reported Alcoholism; Unspecified

Most Recent Events

  • 17 Dec 2024 The US FDA accepts NDA for cyclobenzaprine hydrochloride very low dose for Fibromyalgia for review
  • 15 Dec 2024 Tonix Pharmaceuticals expects a decision on NDA acceptance from the FDA for TNX102 SL in Fibromyalgia
  • 13 Nov 2024 FDA assigns PDUFA action date of December 2024 for TNX 102 SL for fibromyalgia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top